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Abstract
The management of complications in liver disease is of-
ten complex and challenging. Endoscopy has undergone 
a period of rapid expansion with numerous novel and 
specialized endoscopic modalities that are of increasing 
value in the investigation and management of the pa-
tient with liver disease. In this review, relevant literature 
search and expert opinions have been used to provide 
a brief overview and update of the current endoscopic 
management of patients with liver disease and portal 
hypertension. The main areas covered are safety of en-
doscopy in patients with liver disease, the use of stan-
dard endoscopy for the treatment of varices and the 
role of new endoscopic modalities such as endoscopic 
ultrasound, esophageal capsule, argon plasma coagula-
tion, spyglass and endomicroscopy in the investigation 
and treatment of liver-related gastrointestinal and biliary 
pathology. It is clear that the role of the endoscopy in 
liver disease is well beyond that of just treating varices. 
As the technology in endoscopy expands, so does the 
role of the endoscopist in liver disease.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Liver disease and cirrhosis are common causes of  mor-
tality worldwide[1]. The role of  endoscopy in liver dis-
ease is both diagnostic and interventional: endoscopy 
should be offered to patients with relevant symptoms 
(unsuspected liver disease may be diagnosed in this man-
ner) and for variceal screening and treatment. Patients 
with liver disease can be challenging to sedate, and the 
complexity of  endoscopy in liver disease continues to in-
crease with rising numbers of  patients with a liver trans-
plant, and the advent of  new endoscopic modalities such 
as capsule endoscopy and endoscopic ultrasound (EUS). 
SEDATION AND ANALGESIA IN LIVER 
DISEASE
Pharmacodynamics are altered in advanced liver disease as 
a result of  changes in hepatic conjugation and oxidation, 
shunting, decreased protein binding and an increased vol-
World J Gastroenterol  2012 February 7; 18(5): 401-411
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2012 Baishideng. All rights reserved.
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v18.i5.401
401 February 7, 2012|Volume 18|Issue 5|WJG|www.wjgnet.com
Update of endoscopy in liver disease: More than just 
treating varices
Christoforos Krystallis, Gail S Masterton, Peter C Hayes, John N Plevris
Anastasios Koulaouzidis, MD, MRCP, Series Editor
Krystallis C et al . Endoscopy and liver disease
ume of  distribution[2]. The common agents used for seda-
tion in endoscopy are discussed, however, specific doses 
cannot be recommended because these are dependent on 
patient factors. We would recommend that an endoscopist 
or anesthetist who has experience with this patient group 
undertakes the sedation of  liver patients.
Benzodiazepines
Midazolam is the benzodiazepine of  choice in most 
endoscopy units. It is protein bound and metabolized in 
the liver by cytochrome P3A4. In cirrhosis, clearance of  
midazolam is impaired and elimination half-life is dou-
bled. As a result, midazolam should be used with caution 
in patients with cirrhosis[3]. 
Opiates
Pethidine and fentanyl are the most commonly used 
analgesics for endoscopic procedures. The liver is the 
major site of  biotransformation for most opiates. The 
oxidation of  pethidine is reduced in patients with cir-
rhosis and its clearance is diminished. Therefore, there is 
increased bioavailability, and pethidine should be avoided 
in patients with liver disease[4]. The half-life of  fentanyl is 
shorter and does not seem to be influenced by cirrhosis. 
Its use is preferred to pethidine[5].
Anesthetic agents
The pharmacokinetics of  propofol, an anesthetic agent 
that is widely used in endoscopy, appears to be unaf-
fected by cirrhosis; again, perhaps secondary to its short 
half-life. One study has suggested that the use of  propo-
fol rather than midazolam in patients with compensated 
cirrhosis facilitates a faster recovery time with less exac-
erbation of  subclinical encephalopathy[6]. 
Endotracheal intubation
Gastrointestinal (GI) bleeding in patients with liver dis-
ease may be life threatening. If  bleeding varices are sus-
pected or patients are hemodynamically unstable, there 
is often a low threshold for endotracheal intubation to 
protect the airway. There is little literature on prophylac-
tic intubation for airway protection in such patients, and 
two retrospective studies[7,8] have concluded that it does 
not prevent cardiopulmonary complications, or pneu-
monia. We are of  the opinion that airway protection at 
emergency endoscopy is extremely important in patients 
with suspected variceal bleeding, who present with he-
matemesis, and particularly in hemodynamically unstable 
patients and those with hepatic encephalopathy or alco-
hol withdrawal symptoms. In such patients, endoscopy 
is best undertaken in a critical care environment with 
immediate access to anesthetic support and endotracheal 
intubation[9]. 
ENDOSCOPY IN THE CIRRHOTIC PATIENTS 
WITH COAGULATION ABNORMALITIES 
Coagulopathy and thrombocytopenia are common in pa-
tients with chronic liver disease. The mechanisms behind 
coagulation abnormalities are often complex, and it is now 
thought that prolongation of  prothrombin time may not 
directly relate to the risk of  bleeding, and rather, it is the 
balance of  pro- and antithrombotic factors that is impor-
tant. In practical terms, there is currently no reliable way 
of  quantifying this. Routine correction of  coagulopathy 
at endoscopy is not recommended, although patients with 
chronic liver disease should receive vitamin K to correct 
any dietary deficiency that may result in coagulopathy. 
It is recognized that diagnostic endoscopy is a low-
risk procedure and safe in patients with altered co-
agulation. However, high-risk endoscopic therapeutic 
procedures have a significantly increased risk of  hemor-
rhage and, as such, coagulopathy should be treated[10]. 
It is therefore common practice in cirrhotic patients to 
correct significant thrombocytopenia (< 50 × 106/mL) 
with platelet transfusions and to correct coagulopathy 
with fresh frozen plasma (FFP) if  prothrombin time is 
> 20 s to an international normalized ratio < 1.5, before 
high-risk procedures. Platelet and FFP transfusions are 
particularly helpful during an acute bleeding episode if  
the prothrombin time is prolonged or platelets are low, 
similar to the previously mentioned values[11]. 
Novel treatments include recombinant factor Ⅶa. 
This has been used as a hemostatic agent in acute vari-
ceal bleeding, but failed to show efficacy in a large ran-
domized study[12]. Another trial has demonstrated that 
addition of  desmopressin does not improve and may 
worsen the efficacy of  terlipressin in controlling acute 
variceal bleeding in cirrhotic patients[13].
Certain endoscopic investigations have been shown 
to be safe in coagulopathic patients with cirrhosis, de-
spite being relatively invasive; EUS-fine needle aspiration 
of  the liver has been shown to be a safe alternative to 
percutaneous liver biopsy, particularly in patients with 
advanced liver disease, coagulopathy and high risk of  
bleeding[14]. At endoscopic retrograde cholangiopan-
creatography (ERCP), endoscopic papillary balloon 
dilation is safer than endoscopic biliary sphincterotomy 
for the treatment of  choledocholithiasis in patients with 
advanced cirrhosis and coagulopathy, because it has a 
reduced risk of  bleeding[15].
COMMON ENDOSCOPIC DIAGNOSES 
AND MANAGEMENT IN PATIENTS WITH 
LIVER DISEASE
Peptic ulcer disease
The correlation between peptic ulcer disease and cir-
rhosis is well described. Both duodenal and gastric ulcers 
are more common in cirrhosis: the reported prevalence 
is 24.1%[16]. It is recognized that the prevalence of  gas-
tric ulceration increases with the severity of  liver disease 
and is related to changes in the hepatic venous pressure 
gradient[16,17].
A high prevalence of  Helicobacter pylori (H. pylori), up 
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to 89%, in patients with cirrhosis has been reported[18]. 
13C urea breath testing and gastric body histology re-
main highly accurate in detecting H. pylori in cirrhosis, 
whereas rapid urease tests and serology are less reliable 
than in non-cirrhotic patients[19]. A meta-analysis of  
seven studies with almost 1000 patients has strongly 
suggested that, as with non-cirrhotic patients, H. pylori 
infection increases the risk for peptic ulcer disease in 
cirrhosis[20]. H. pylori eradication therapy is effective in 
chronic liver disease[21]. However, two recent studies have 
suggested that H. pylori eradication in cirrhotic patients 
with duodenal ulcers is not as effective at reducing ulcer 
recurrence as it is in the general population. These pa-
tients require maintenance acid suppression therapy[22,23].
Portal hypertension
The development of  portal hypertension and formation 
of  portosystemic shunts is a major event in the natu-
ral history of  liver disease. Measurement of  the portal 
pressure gradient is invasive and not widely available for 
clinical use; instead the hepatic venous pressure gradient 
(HVPG) is commonly used in clinical practice and it is 
of  prognostic value: HPVG ≥ 10 mmHg strongly pre-
dicts the development of  esophageal varices[24]. Similarly, 
the most significant risk factor associated with failure to 
control bleeding or early rebleeding of  esophageal vari-
ces is HVPG > 20 mmHg. This is also associated with 
increased mortality[25].
Gastroesophageal varices are present in > 50% of  
patients with portal hypertension and are more likely as 
liver disease progresses[26].  Ectopic varices are located in 
sites other than the gastroesophageal region and are more 
common than previously thought: duodenal or colonic 
varices are seen at angiography or colonoscopy in up to 
40% of  patients with intrahepatic portal hypertension[27].
Esophageal varices
It is recommended that all patients undergo endoscopy 
to assess the presence and the size of  varices at the time 
of  the diagnosis of  cirrhosis. Thereafter, guidelines for 
the interval of  endoscopic screening vary. Currently, 
the American Association for the Study of  the Liver 
(AASLD) recommends that, if  no varices are present at 
index endoscopy, this should be repeated at 2-3 years in 
compensated cirrhosis and annually in decompensated 
cirrhosis[11]. The British Society of  Gastroenterology rec-
ommends annual screening if  grade 1 varices are present 
at initial screening (Table 1, grading and treatment of  
esophageal varices), and an interval of  3 years if  there is 
no evidence of  varices at index endoscopy[28].
Esophageal variceal bleeding occurs at a rate of  
5%-15% per year in untreated patients. The main risk 
factors for bleeding are variceal size (grade 2 or 3), de-
compensated cirrhosis, and the presence of  high-risk 
stigmata at endoscopy[29]. Variceal bleeding is a significant 
clinical event with a mortality rate of  approximately 20% 
at 6 wk, and a recurrence rate of  up to 60% at 2 years if  
secondary prophylaxis is not commenced[30].
The management of  esophageal varices may be di-
vided into pre-primary, primary and secondary prophy-
laxis and control of  active bleeding. At present, there 
is no evidence to support treatment to prevent the de-
velopment of  varices in patients with liver disease (pre-
primary prophylaxis)[31,24].
For primary prophylaxis of  esophageal varices, there 
is no evidence that variceal band ligation (VBL) is supe-
rior to β-blockade. Due to issues with access to endos-
copy and patient preference, non-selective β-blockade, 
typically with propranolol, is often first line when treat-
ment is indicated[32]. Carvedilol is a potent non-selective 
β-blocker, with weak vasodilating properties. A reduc-
tion in the HVPG in the range of  10%-43% has been 
reported with a 12.5 mg/d dose. Carvedilol has therefore 
been adopted as the β-blocker of  choice for primary 
prophylaxis of  variceal bleeding in some centers[33-35]. 
Primary prophylaxis with VBL is recommended if  there 
are contraindications to β-blockers, or concerns about 
patient compliance[11].  
Secondary prophylaxis is indicated for patients who 
have had an episode of  variceal hemorrhage. β-blocker 
monotherapy is not used as secondary prophylaxis, and 
patients should either be entered into a variceal banding 
program or receive a combination of  a β-blocker and ni-
trate[36]. AASLD recommends a combination of  β block-
ade and VBL[11]. However, there is no strong evidence 
to suggest that this strategy is associated with improved 
mortality[37] and our local practice is to use VBL alone. 
VBL should be repeated every 2 wk until obliteration of  
varices is achieved. Following this, a surveillance endos-
copy at 1-3 mo to confirm eradication is required, and 
this should be repeated every 6-12 mo[11]. VBL is a safe 
technique: although asymptomatic banding ulcers are 
common after VBL, the rate of  bleeding from these and 
requiring hospitalization does not exceed 5%[38].
The combination of  terlipressin and VBL is the 
preferred treatment for acute variceal bleeding in many 
centers, and using terlipressin before endoscopy is not 
unreasonable if  there is a delay to the endoscopy. Endo-
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  Grade Appearance High-risk stigmata Treatment
  Grade 1: Small varices Barely noticeable varices; disappear easily with insufflation No red signs No treatment
  Grade 2: Small/medium varices Small or medium varices; do not easily disappear with insufflation ± Red signs NSBB or VBL
  Grade 3: Medium/large varices Medium or large varies; do not disappear with insufflation ± Red signs NSBB or VBL 
Table 1  Summary of primary prophylaxis of esophageal varices
NSBB: Non-selective b blockers; VBL: Variceal band ligation.
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scopic hemostasis is usually achieved in the majority of  
cases[11]. Transjugular intrahepatic portal systemic shunt 
(TIPSS) may be considered if  VBL has been unsuccess-
ful or there is an early re-bleed (defined at Baveno V as a 
repeat bleed within 5 d of  the index bleed). A reduction 
in HVPG below 12 mmHg or a 20% reduction from the 
baseline value, even without reaching < 12 mmHg, pro-
tects against rebleeding[39]. 
The use of  sclerosing agents (variceal sclerotherapy) 
is no longer recommended as first-line treatment, be-
cause of  increased mortality rates[40], nor for secondary 
prophylaxis because VBL treatment has been shown to 
be safer and more effective[41]. 
Recently, endoscopic placement of  a specifically de-
signed self-expanding covered metal stent has proved 
effective in the treatment of  esophageal varices in pa-
tients in whom initial endoscopic methods have failed to 
achieve hemostasis[42]. This method appears to be a safe 
and effective means of  controlling ongoing bleeding. The 
stent is usually removed 1 wk after the acute bleed. Cur-
rently, this technique is limited by its relative complexity 
of  stent insertion in acute bleeding, but stenting with 
covered biodegradable stents when available, which do 
not require removal, may play an important role in the 
management of  acute esophageal variceal bleeding[43]. 
Gastric and ectopic varices
Gastric varices are less prevalent than esophageal varices 
and less prone to bleeding: around 25% over a 2-year 
period[44]. There is no evidence to support the primary 
prophylaxis of  gastric varices. The tissue adhesive cya-
noacrylate (“glue”) is used widely in the management of  
acutely bleeding gastric varices. Cyanoacrylate is a liquid 
with consistency similar to water, which when added to a 
physiological fluid like blood, polymerizes to form a sol-
id substance[45]. Two randomized controlled studies have 
compared cyanoacrylate with VBL for management of  
bleeding gastric varices[46,47]. In one study, cyanoacrylate 
was more effective than VBL in achieving homeostasis, 
and in the second, no difference was reported, although 
both reported less recurrence of  bleeding. Current evi-
dence suggests that cyanoacrylate achieves control of  
bleeding in 87%-93% of  cases, and that bleeding-related 
mortality is between 6.5% and 10%[46,47].  
The use of  bovine or more recently, human throm-
bin has been described as an alternative treatment for 
active gastric variceal bleeding. Thrombin [activated fac-
tor Ⅱ (Ⅱa)] is a serine protease that converts soluble 
fibrinogen into insoluble strands of  fibrin clot. It has 
additional effects including promotion of  platelet ag-
gregation. Initial hemostasis rates have been reported 
at 94%-100%, and rebleeding rates of  between 23% 
and 25%[48,49]. A single center experience of  13 patients 
treated with thrombin for bleeding gastric varices has 
reported efficient hemostasis and an overall mortality of  
38% in a median follow-up of  22 mo[50]. 
Technical difficulties that include the risk of  equip-
ment damage and reports of  severe thromboembolic 
complications may limit the use of  cyanoacrylate, and 
thrombin (Figure 1) may become more widespread in 
the future[51,52]. 
The role of  TIPSS as primary treatment in actively 
bleeding gastric varices has also been explored. Although 
TIPSS has a comparable mortality and rebleeding rate 
to cyanoacrylate, it is associated with significantly higher 
morbidity and is not used as first-line treatment[53,54], but 
remains an effective treatment when endoscopy fails to 
control bleeding.
Nonvariceal manifestations of portal hypertension
Portal hypertensive gastropathy (PHG), with its typical 
“snake skin” appearance, is present in approximately 
80% of  patients with cirrhosis[55]. PHG accounts for 
8% of  nonvariceal bleeds in patients with liver disease, 
although this condition more commonly presents with 
anemia[56]. Patients with cirrhosis and severe PHG-
related bleeding may respond to β-blockade. Endoscopic 
measures such as argon plasma coagulation (APC) ther-
apy can reduce bleeding, thus controlling anemia. TIPSS 
should be reserved for those patients with pharmaco-
logical treatment failure[57].  
The prevalence of  portal hypertensive enteropathy 
(PHE), determined by capsule endoscopy, is as high as 
63% in patients with end-stage liver disease who also have 
esophageal or gastric varices[58]. Portal hypertensive duode-
nopathy is present in around half  of  patients with cirrho-
sis, and it is more common in patients with severe PHG[59]. 
Gastric antral vascular ectasia
Gastric antral vascular ectasia (GAVE) is related to por-
tal hypertension in about 30% of  patients, and accounts 
for 4% of  nonvariceal upper GI bleeds[60]. Unlike PHG, 
GAVE does not respond well to reduction in portal pres-
sure[61]. The Nd:YAG laser has been widely used in the 
treatment of  GAVE and is the most commonly reported 
endoscopic modality in cirrhotic and non-cirrhotic pa-
tients, with a reported overall success rate of  almost 90%, 
although the authors did not distinguish the etiology of  
GAVE when reporting the outcomes[62].
APC has also proved to be effective for the treatment 
of  GAVE-related bleeding, and it is extensively used in 
our unit, with a success rate of  > 85%; success is defined 
as control of  bleeding, stabilization of  hemoglobin at > 
100 g/dL, or hemoglobin increase > 10% from pretreat-
ment level, and reduction of  transfusion requirements by 
> 50% in transfusion-dependent patients. An average of  
four sessions of  APC is usually required (Figures 2 and 3). 
In two published studies, with a total of  37 patients with 
cirrhosis, success rates in controlling bleeding were very 
high, and the reported rebleeding rates were between 
12% and 20% after 2 years follow-up[62,63].
Although the success rates of  the two aforemen-
tioned modalities are comparable, APC treatment is 
probably the therapy of  choice due to the technical ease, 
safety and low cost[61]. Other endoscopic techniques have 
been positively reported in small series, such as VBL[64], 
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endoscopic mucosal ablation[65] and cryotherapy[66]. 
ADVANCED ENDOSCOPIC PROCEDURES 
AND THEIR VALUE IN LIVER DISEASE
EUS
Recently, EUS has been used to assist in the management 
of  portal hypertension. Doppler EUS is of  significant 
value in differentiating ectopic varices from other submu-
cosal lesions[67] (Figure 4), and several EUS-assisted tech-
niques have been used to identify the precise site for the 
intravariceal injection of  sclerosant agents. Linear color 
EUS-guided sclerotherapy has proved to be effective in 
the eradication of  esophageal varices, in two small stud-
ies with recurrence reported at 0% and 8.3%, respective-
ly[68,69]. EUS catheter probes and high-frequency (20 MHz) 
miniprobes have both been used successfully before and 
after esophageal variceal sclerosant injection in two differ-
ent studies to assess eradication and variceal recurrence. 
After a mean follow-up of  24 mo, variceal recurrence was 
reported at 16.6% and 26.3%, respectively[70,71]. 
Although the overall patient numbers are small, lin-
ear EUS seems to be the superior modality in assisting 
treatment of  esophageal varices, because it permits the 
targeting of  the feeding vessels. 
EUS-assisted injection of  cyanoacrylate for the treat-
ment of  gastric varices has been described in 54 patients 
with a mean follow-up of  24 mo. Varices recurred in 
35% of  patients[72]. Furthermore, a series of  15 patients 
with gastric or ectopic varices treated with thrombin in-
jection in conjunction with a variety of  EUS techniques 
(Figure 5) has recently been reported in our unit, and 
this proved to be effective in controlling active bleeding 
and achieving variceal eradication[73]. 
Capsule endoscopy 
Esophageal capsule endoscopy (OCE) is an alternative 
to conventional upper GI endoscopy for the diagnosis 
of  varices in complex patients with portal hypertension. 
In a recent meta-analysis of  seven studies involving 446 
patients, OCE had a sensitivity of  85.8% and specific-
ity 80.5% in detecting esophageal varices[74].  However, 
a multicenter trial evaluating the efficacy of  OCE in 
esophageal varices screening was less encouraging, be-
cause the standard of  < 10% difference between capsule 
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A B
Figure 2  Endoscopic image. A: Gastric antral vascular ectasia (GAVE) (diffuse 
type) with active bleeding prior to argon plasma coagulation (APC) treatment; B: 
GAVE (diffuse type) immediately after APC treatment.
A B
Figure 3  Endoscopic image. A: Gastric antral vascular ectasia-induced symp-
tomatic anemia; B: Endoscopic image of the same patient 2 years later, after 
several argon plasma coagulation sessions. The number of angioectatic lesions 
in the gastric outlet had dramatically decreased.
A B
Figure 4  Endoscopic image of gastric irregular submucosal lesion. A: Gas-
tric irregular submucosal lesion in a patient with portal hypertension; B: The same 
lesion examined under color Doppler endoscopic ultrasound. The submucosal 
lesion was hypervascular and represented a gastric varix.
A B C D
Figure 1  Endoscopic images of fundic gastric varices before (A), during (B, C) and after (D) thrombin injection.
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and conventional endoscopy was not met[75]. This is not 
surprising, because the two techniques differ in that dur-
ing conventional endoscopy, the esophagus is inevitably 
insufflated with air and varices can appear more flat-
tened than during OCE examination. Further studies to 
take this into account are necessary. Nevertheless, OCE 
remains a useful tool for screening of  varices in certain 
patient groups; patients who poorly tolerate endoscopy 
or who have significant comorbidity, thus increasing the 
risks of  repeated endoscopy, and patients with high risk 
of  variant Creutzfeldt-Jakob disease. Although this tech-
nique is limited by availability and high costs, OCE can 
be cost-effective for variceal screening of  patients with 
coagulation abnormalities (e.g., hemophilia) with coexist-
ing liver disease, because it does not require prophylactic 
clotting factor administration, unlike conventional en-
doscopy. Serial capsule examinations in the same patient 
may provide significant diagnostic information regarding 
progression of  varices. 
Small bowel capsule endoscopy (SBCE) has been 
used to characterize PHE (Figure 6), and is of  value in 
the diagnosis of  this condition in patients with advanced 
liver disease who continue to bleed despite treatment of  
esophageal/gastric varices or portal gastropathy (Figure 7). 
The role of  SBCE in portal hypertension has yet to be 
defined, but it is likely that it will remain a valuable tool 
in certain groups of  patients with liver disease.
Endoscopic retrograde cholangiography
Primary sclerosing cholangitis (PSC) is characterized by 
fibrosis of  both intrahepatic and/or extrahepatic biliary 
ducts. These patients are at risk of  developing infectious 
cholangitis and up to 20% develop cholangiocarcinoma. 
A strategy of  initial magnetic resonance cholangiopan-
creatography (MRCP) followed, if  necessary, by ERCP is 
currently the most cost-effective approach to the work-
up of  patients with suspected sclerosing cholangitis[76]. 
ERCP plus diagnostic brushing have a sensitivity of  
60%-100%, and specificity of  85%-89% in differentiating 
between a benign dominant stricture and cholangiocarci-
noma[77,78]. Recently, two advanced cytological techniques 
(digital image analysis and fluorescence in situ hybridiza-
tion) have been used for the detection of  malignancy in 
PSC-related strictures and have proved to be more sensi-
tive and equally specific to conventional cytology[79]. 
In addition, ERCP permits therapeutic interventions 
with balloon dilation or stent placement as appropriate.
Novel techniques and the biliary tree
Novel endoscopic modalities have been compared with 
conventional ERCP and brush cytology. Transpapillary 
cholangioscopy with tissue sampling has proved to be 
more sensitive (92% vs 66%) and specific (93% vs 51%) 
than ERCP to detect cholangiocarcinoma in PSC[80]. In 
a small study, narrow band imaging has demonstrated 
superior visualization of  biliary lesions compared with 
conventional white light imaging[81]. In another study, 
transpapillary intraductal ultrasound was superior to 
ERCP for the detection of  cholangiocarcinoma in PSC 
in terms of  sensitivity (87.5% vs 62.5%) and specificity 
(90.6% vs 53.1%)[82].
SpyglassTM is a new single-operator system used for 
the diagnosis of  a variety of  pancreatobiliary disorders, 
such as the definition of  indeterminate strictures and 
filling defects prior to stone extraction[83]. Although the 
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Figure 5  Color doppler endoscopic ultrasound image of duodenal varices 
after thrombin injection. The absence of blood flow and the speckled appear-
ances were suggestive of thrombus formation.
Figure 6  Small bowel capsule image of portal hypertensive enteropathy 
and stigmata of recent bleeding. Engorged small bowel villi and micro-
hemorrhagic spots were visible.
Figure 7  Small bowel capsule image of portal hypertensive enteropathy 
with snake-skin-like appearance of the mucosa and red spots as stigmata 
of recent bleeding.
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initial experience  is promising, the modality has been 
only been tested in a limited number of  PSC-related 
strictures, and unlike ERCP, this is a purely diagnostic 
technique.
Confocal laser endomicroscopy (“miniprobe”) is a 
new field of  endoluminal imaging that offers extremely 
high magnification and resolution. This technique allows 
visualization of  pancreatic and biliary ducts. In a pilot 
study of  14 patients with biliary strictures, miniprobe-
based microscopy after fluorescein administration proved 
to be more accurate than brushings and biopsy in distin-
guishing benign from malignant strictures (Figure 8)[84].
A novel alternative is direct cholangioscopy using 
ultra-slim endoscopes (4.9-5.9 mm). These endoscopes, 
initially developed for transnasal endoscopy, can be safe-
ly inserted into the bile duct following sphincterotomy, 
and not only permit high-resolution images, but also 
biopsy and other interventional procedures in the bile 
ducts, such as hydraulic lithotripsy and division of  stric-
tures in benign biliary disease. This technique is currently 
under development and after a full range of  endoscopic 
accessories are available for endobiliary interventions, it 
could be an effective and safe approach for patients with 
difficult to manage biliary disease[85].
Endoscopic modalities in the lower GI tract
In comparison to the upper GI tract, colonic manifesta-
tions of  portal hypertension much less often present 
with acute bleeding, and are more often found inciden-
tally or during investigation of  anemia. As such, data are 
sparse and less consistent. The reported prevalence of  
portal hypertensive colonopathy is 24%[86].
The most significant feature of  portal hypertension 
in the colon is arguably the presence of  rectal varices. 
These can be present in up to 44% of  patients with cir-
rhosis at colonoscopy, although the reported prevalence 
varies widely. They are more frequent in patients with 
advanced liver disease[87].
Although bleeding from rectal varices is uncommon, 
it can be life threatening. Due to their rarity, no firm 
guidelines have been established for the management of  
bleeding colonic varices, and there is a limited evidence 
base. The most commonly used treatment modalities are 
sclerotherapy and band ligation. In a small retrospective 
comparative study of  15 patients, endoscopic injection 
sclerotherapy proved to be superior to endoscopic band 
ligation and achieved lower recurrence rates[88]. In our 
unit, thrombin has been successfully used to manage 
rectal variceal bleeding. Patients may require TIPSS if  
bleeding cannot be controlled endoscopically.
ENDOSCOPY AND THE LIVER 
TRANSPLANT PATIENT
Luminal diseases in liver transplant patients
Peptic ulcer disease is the most common cause of  GI 
bleeding in post-orthotopic liver transplant (OLT) recipi-
ents, accounting for 27% of  all bleeding[89]. Varices rarely 
recur post-transplant, and if  present, require investigation 
to exclude portal vein thrombosis or disease recurrence[90]. 
Liver transplant patients are at increased risk of  op-
portunistic infections, particularly candidiasis and cyto-
megalovirus[91]. These often present with GI symptoms 
and require endoscopic evaluation with biopsies or 
brushings to confirm the diagnosis. 
The association of  PSC with ulcerative colitis is well 
recognized and is an additional risk factor for the de-
velopment of  colorectal cancer in immunosuppressed 
transplant patients. It is currently recommended that 
these patients have an annual surveillance colonos-
copy commencing 10 years after the onset of  bowel 
symptoms[92]. Colectomy is safe in patients who have 
undergone OLT, and in some high-risk cases, such as 
when high-grade dysplasia has already been identified, a 
prophylactic colectomy may be performed at the time of  
transplantation[93].
Transplant-related biliary disease
Biliary complications (biliary strictures and leaks) follow-
ing liver transplantation are a challenging and common 
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Figure 8  Endomicroscopy image. A: Image from Cellvizio® bile duct endomicroscopy. The regular reticular pattern of thin dark structures with low signal (dark) 
characterized the normal bile duct (Image courtesy of www. cellvizio.net); B: Abnormal bile duct appearances in Cellvizio® endomicroscopy; isolated blood vessels 
with very strong signal (with strands) suggestive of tumor neovascularization of cholangiocarcinoma (Image courtesy of www.cellvizio.net); C: Reticular pattern of dark 
bands and dark clumps or glands suggestive of cholangiocarcinoma (Image courtesy of www.cellvizio.net).
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tal cancer in high-risk patients. Biliary complications are 
common after transplantation and ERCP is the modality 
of  choice for treating such patients. 
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